Combined Biomarker Approach Using Extracellular Vesicles, Donor-Derived Cell-Free DNA, and Donor-Specific Antibodies for Monitoring Renal Allograft Function: A Narrative Review
Medicina · 31.03.2026 · 62 (4) · 664
DOI: 10.3390/medicina62040664 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Medicina, online erschienen am 31.03.2026. Verfasst von Kumar Digvijay und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. Hauptthemen laut MEDLINE: Biomarkers, Extracellular Vesicles, Kidney Transplantation, Cell-Free Nucleic Acids. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: Renal transplantation is the optimal treatment for end-stage renal disease, yet long-term allograft survival remains threatened by immune-mediated injury and chronic nephropathy. Conventional monitoring using serum creatinine and protocol biopsy suffers from limited sensitivity for early, subclinical injury. Liquid biopsy-based biomarkers offer a non-invasive alternative. Materials and Methods: We conducted a systematic narrative review of studies published between January 2010 and December 2024, identified through PubMed, Scopus, and Web of Science.
Results
Extracellular vesicles carry injury-specific molecular cargo reflecting the biological state of tubular, glomerular, and endothelial cells; urinary EV CXCL9 protein and exosomal CD3ε mRNA have demonstrated AUC values of 0.81–0.88 for the detection of T-cell-mediated rejection. Donor-derived cell-free DNA quantifies global graft cell death; the FDA-cleared AlloSure assay achieves an AUC of 0.74 and NPV of 84% at the validated ≥1.0% threshold established in the DART trial. Donor-specific antibodies—particularly complement-fixing C1q-positive DSAs—confer markedly inferior 5-year graft survival compared with DSA-negative recipients (54% versus 93%). Multi-biomarker panels integrating all three modalities yield AUCs of 0.88–0.94 and NPVs of 91–95%.
Conclusions
The integration of EV, ddcfDNA, and DSA monitoring into a unified surveillance framework offers a clinically meaningful advance over creatinine-based monitoring. Prospective randomized trials confirming improvement in long-term allograft survival will be the critical next step.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Renal Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark.
ORCID-Profile: Kumar Digvijay, Henrik Birn
Zitieren
APA
Digvijay, K., & Birn, H. (2026). Combined Biomarker Approach Using Extracellular Vesicles, Donor-Derived Cell-Free DNA, and Donor-Specific Antibodies for Monitoring Renal Allograft Function: A Narrative Review. Medicina, 62(4), 664. https://doi.org/10.3390/medicina62040664
Vancouver
Digvijay K, Birn H. Combined Biomarker Approach Using Extracellular Vesicles, Donor-Derived Cell-Free DNA, and Donor-Specific Antibodies for Monitoring Renal Allograft Function: A Narrative Review. Medicina. 2026;62(4):664. doi:10.3390/medicina62040664
BibTeX
@article{Digvijay2026,
author = {Digvijay, Kumar and Birn, Henrik},
title = {Combined Biomarker Approach Using Extracellular Vesicles, Donor-Derived Cell-Free DNA, and Donor-Specific Antibodies for Monitoring Renal Allograft Function: A Narrative Review},
journal = {Medicina},
year = {2026},
volume = {62},
number = {4},
pages = {664},
doi = {10.3390/medicina62040664}
}
EUVIMED